ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4937
0.16%
Brent Oil
81.95
-0.21%
Bitcoin
66,440.04
-0.30%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Calidi Biotherapeutics Inc (CLDI)

  7. Calidi Biotherapeutics Inc (CLDI) Noticias

CLDI

Calidi Biotherapeutics (CLDI)

Calidi Biotherapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:CLDI
FechaHoraFuenteTítuloSímboloCompañía
11/06/202415:05Business WireCalidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13AMEX:CLDICalidi Biotherapeutics Inc
10/06/202406:00Business WireCalidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid TumorsAMEX:CLDICalidi Biotherapeutics Inc
03/06/202406:00Business WireCalidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual MeetingAMEX:CLDICalidi Biotherapeutics Inc
31/05/202407:51Business Wire Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross ProceedsAMEX:CLDICalidi Biotherapeutics Inc
14/05/202415:05Business WireCalidi Biotherapeutics Reports First Quarter 2024 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
01/05/202406:00Business WireCalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingAMEX:CLDICalidi Biotherapeutics Inc
23/04/202406:00Business WireJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24AMEX:CLDICalidi Biotherapeutics Inc
19/04/202415:05Business WireCalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public OfferingAMEX:CLDICalidi Biotherapeutics Inc
16/04/202407:31Business WireCalidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public OfferingAMEX:CLDICalidi Biotherapeutics Inc
09/04/202406:00Business WireCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024AMEX:CLDICalidi Biotherapeutics Inc
15/03/202415:05Business WireCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
11/03/202406:00Business WireCalidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian CancerAMEX:CLDICalidi Biotherapeutics Inc
12/02/202406:00Business WireCalidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming ConferenceAMEX:CLDICalidi Biotherapeutics Inc
08/01/202406:00Business WireCalidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory BoardAMEX:CLDICalidi Biotherapeutics Inc
13/12/202306:00Business WireCalidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy SummitAMEX:CLDICalidi Biotherapeutics Inc
12/12/202306:00Business WireCalidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of DirectorsAMEX:CLDICalidi Biotherapeutics Inc
20/11/202306:00Business WireCalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical MilestonesAMEX:CLDICalidi Biotherapeutics Inc
14/11/202315:05Business WireCalidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
03/11/202306:00Business WireCalidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)AMEX:CLDICalidi Biotherapeutics Inc
01/11/202306:00Business WireCalidi Biotherapeutics Announces Key Leadership Promotions and New Board AppointmentAMEX:CLDICalidi Biotherapeutics Inc
30/10/202306:00Business WireCalidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial OfficerAMEX:CLDICalidi Biotherapeutics Inc
10/10/202306:00Business WireCalidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023AMEX:CLDICalidi Biotherapeutics Inc
13/09/202304:50Business WireCalidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted ImmunotherapiesAMEX:CLDICalidi Biotherapeutics Inc
 Showing the most relevant articles for your search:AMEX:CLDI

Su Consulta Reciente

USOTC
ADDYY
Adidas (QX)
CCOM
US500
US 500
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
NASDAQ
NVDA
NVIDIA
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
XLF
Financial Select Sector
FX
USDMXN
US Dollar vs MXN
NYSE
NKE
Nike
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
CCOM
OILBRENT
Brent Oil
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados